Vanta Bioscience
24.93
+1.18(+4.97%)
Market Cap₹17.74 Cr
PE Ratio158.33
IndustryHealthcare
Company Performance:
1D+4.97%
1M+38.50%
6M+21.67%
1Y-10.29%
5Y-83.74%
View Company Insightsright
More news about Vanta Bioscience
01Aug 25
Vanta Bioscience Reports Significant Losses for FY2025 Amid Revenue Decline
Vanta Bioscience Limited, a preclinical contract research organization, reported a substantial net loss for FY2025. Standalone net loss was Rs 265.95 lakh, compared to a profit of Rs 5.11 lakh in the previous year. Revenue from operations declined by 86.80% to Rs 112.74 lakh. Consolidated results showed a net loss of Rs 477.49 lakh, with revenue falling by 79.80% to Rs 196.36 lakh. The company faced operational challenges, including delays in consolidating financial results due to late receipt of accounts from an associate company. Despite financial difficulties, total assets increased by 2.52% to Rs 52.90 crore, while current liabilities rose by 39.22% to Rs 14.20 crore.
 no imag found
Vanta Bioscience
24.93
+1.18
(+4.97%)
1 Year Returns:-10.29%
Industry Peers
Syngene International
440.30
(-1.78%)
Indegene
518.60
(+0.52%)
Suven Life Sciences
259.70
(-1.16%)
Vimta Labs
567.10
(+4.66%)
Take Solutions
29.76
(+0.34%)
Bilcare
56.50
(-2.57%)
Adeshwar Meditex
15.00
(0.0%)
Vanta Bioscience
24.93
(+4.97%)